无创诊断和评估非酒精性脂肪性肝炎研究进展*

doi:10.3969/j.issn.1672-5069.2019.02.038

摘要/Abstract

摘要： 非酒精性脂肪性肝病（NAFLD）主要包括单纯性脂肪肝（NAFL)、非酒精性脂肪性肝炎（NASH）、相关肝硬化和肝细胞癌。相对于NAFL,NASH更易发展为肝硬化和肝癌,故早期诊断并对其干预尤为重要。近年来,多项无创诊断方法的出现致力于替代肝脏穿刺活检,主要包括血清学和影像学检查等,本文就无创性诊断和评估NASH作一综述。

关键词: 非酒精性脂肪性肝病, 非酒精性脂肪性肝炎, 无创诊断, 评估

Abstract: Nonalcoholic fatty liver disease （NAFLD） includes a spectrum of diseases ranging from nonalcoholic fatty liver （NAFL） to nonalcoholic steatohepatitis （NASH）,cirrhosis and eventually to hepatocellular carcinoma （HCC）. NASH has an increased risk for advanced cirrhosis and HCC,so there has been an urgent need to accurately distinguish between NAFL and NASH and intervene its further development in early time. In recent years,many noninvasive diagnostic methods including serological markers and imaging examination were applied in clinical practice trying to replace liver biopsy. This article reviews the noninvasive diagnosis and evaluation of NASH.

Key words: Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Noninvasive diagnosis, Assessment

谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.

Xie Xiao, Lu Lungen. Noninvasive diagnosis and assessment of patients with nonalcoholic steatohepatitis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 301-306.

参考文献

[1] Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases. Hepatology,2018,67(1):328-357.
[2] Fazel Y,Koenig AB,Sayiner M,et al.Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism,2016,65(8):1017-1025.
[3] Marengo A,Jouness RI,Bugianesi E,et al.Progression and natural history of nonalcoholic fatty liver disease in adults. Clin Liver Dis,2016,20(2):313-324.
[4] Kleiner DE,Brunt EM,Van Natta M,et al.Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology,2005,41(6):1313-1321.
[5] Bedossa P,Poitou C,Veyrie N,et al.Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology,2012,56(5):1751-1759.
[6] Verhaegh P,Bavalia R,Winkens B,et al.Non-invasive tests do not accurately differentiate non-alcoholic steatohepatitis from simple steatosis:asystematic review and meta-analysis. Clin Gastroenterol Hepatol,2017 [Epub ahead of print].
[7] Alkhouri N,Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease:Are we there yet Metabolism,2016,65(8):1087-1095.
[8] Boga S,Koksal AR,Alkim H,et al.Plasma pentraxin 3 differentiates nonalcoholic steatohepatitis(NASH) from non-NASH. Metab Syndr Relat Disord,2015,13(9):393-399.
[9] Kowdley KV,Belt P,Wilson LA,et al.Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology,2012,55(1):77-85.
[10] Angulo P,George J,Day CP,et al.Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol,2014,12(7):1163-1169.
[11] Hagstrom H,Nasr P,Bottai M,et al.Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. Liver Int,2016,36(11):1688-1695.
[12] Tsutsui M,Tanaka N,Kawakubo M,et al.Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J Clin Gastroenterol,2010,44(6):440-447.
[13] Aida Y,Abe H1,Tomita Y,et al. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease. Int J Clin Exp Med,2014,7(11):4191-4198.
[14] Alkhouri N,Alisi A,Okwu V,et al.Circulating soluble fas and fas ligand levels are elevated in children with nonalcoholic steatohepatitis. Dig Dis Sci,2015,60(8):2353-2359.
[15] Kamada Y,Akita M,Takeda Y,et al.Serum fucosylated haptoglobin as a novel diagnostic biomarker for predicting hepatocyte ballooning and nonalcoholic steatohepatitis. PLoS One,2013,8(6):e66328.
[16] Kamada Y,Ono M,Hyogo H,et al.A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology,2015,62(5):1433-1443.
[17] Koo BK,Joo SK,Kim D,et al.Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. J Gastroenterol Hepatol,2017 [Epub ahead of print].
[18] Liu X,Wang Y,Ming Y,et al.S100A9:A potential biomarker for the progression of non-alcoholic fatty liver disease and the diagnosis of non-alcoholic steatohepatitis. PLoS One,2015,10(5):e0127352.
[19] Qi S,Xu D,Li Q,et al.Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis. Clin Chim Acta,2017,473:89-95.
[20] Gutierrezbuey G,Núnezcórdoba J M,Llaverovalero M,et al.Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes Eur J Intern Med,2017,41:74.
[21] Golabi P,Sayiner M,Fazel Y,et al.Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol,2016,10(1):63-71.
[22] Bedogni G,Bellentani S,Miglioli L,et al.The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol,2006,6(1):33.
[23] Otgonsuren M,Estep MJ,Hossain N,et al.Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis(NASH). J Gastroenterol Hepatol,2014,29(12):2006-2013.
[24] Schwenzer NF,Springer F,Schraml C,et al.Non-invasive assessment and quantification of liver steatosis by ultrasound,computed tomography and magnetic resonance. J Hepatol,2009,51(3):433-445.
[25] Park SH,Kim PN,Kim KW,et al.Macrovesicular hepatic steatosis in living liver donors:use of CT for quantitative and qualitative assessment. Radiology,2006,239(1):105-112.
[26] Lee DH.Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. Clin Mol Hepatol,2017,23(4):290-301.
[27] Tang A,Desai A,Hamilton G,et al.Accuracy of MR imaging-
estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology,2015,274(2):416-425.
[28] Noureddin M,Lam J,Peterson MR,et al.Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology,2013,58(6):1930-1940.
[29] Sasso M,Beaugrand M,de Ledinghen V,et al. Controlled attenuation parameter (CAP):a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis:preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol,2010,36(11):1825-1835.
[30] Vuppalanchi R,Siddiqui MS,Van Natta ML.et al.Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology,2018,67(1):134-144.
[31] Tribonias G,Margariti E,Tiniakos D,et al.Liver function breath tests for differentiation of steatohepatitis from simple fatty liver in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol,2014,48(1):59-65.
[32] Verdam FJ,Dallinga JW,Driessen A,et al.Non-alcoholic steatohepatitis:a non-invasive diagnosis by analysis of exhaled breath. J Hepatol,2013,58(3):543-548.
[33] Arasaradnam RP,McFarlane M,Daulton E,et al. Non-invasive distinction of non-alcoholic fatty liver disease using urinary volatile organic compound analysis:early results. J Gastrointestin Liver Dis,2015,24(2):197-201.
[34] Park GJ,Wiseman E,George J,et al.Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test. J Gastroenterol Hepatol,2011,26(9):1411-1616.

无创诊断和评估非酒精性脂肪性肝炎研究进展^*

Noninvasive diagnosis and assessment of patients with nonalcoholic steatohepatitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[3]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[4]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[5]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[6]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[7]	巴正武, 栗海龙, 杨慧. 能谱CT成像定量评估Budd-Chiari综合征患者TIPS术治疗前后肝功能状态临床价值研究*[J]. 实用肝脏病杂志, 2019, 22(5): 680-683.
[8]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[9]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[10]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[11]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[12]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[13]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[14]	张枫, 阎妍. 非酒精性脂肪性肝病患者血清载脂蛋白B水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 61-64.
[15]	宋娜, 刘晓燕, 刘畅, 山秀杰, 苏东峰, 李丽慧. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(1): 65-68.